The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer.
Yasushi Sato
No relevant relationships to disclose
Hiroyuki Ohnuma
No relevant relationships to disclose
Masahiro Hirakawa
No relevant relationships to disclose
Minoru Takahashi
No relevant relationships to disclose
Takahiro Osuga
No relevant relationships to disclose
Kohichi Takada
No relevant relationships to disclose
Tsuyoshi Hayashi
No relevant relationships to disclose
Tsutomu Sato
No relevant relationships to disclose
Koji Miyanishi
No relevant relationships to disclose
Rishu Takimoto
No relevant relationships to disclose
Masayoshi Kobune
No relevant relationships to disclose
Kenji Okita
No relevant relationships to disclose
Tomohisa Furuhata
No relevant relationships to disclose
Koichi Hirata
No relevant relationships to disclose
Junji Kato
No relevant relationships to disclose